Delirium
Sumeet Singh-Tan
Nicholas E.S. Sibinga
<p>Vascular disease, the greatest single cause of morbidity and mortality in developed societies, results from interactions between circulating inflammatory cells, the endothelium that lines the vasculature, underlying vascular smooth muscle cells (VSMCs) that comprise most of the arterial wall, and stem/progenitor cells found in the surrounding adventitia. The underlying pathogenesis is complex: factors that impinge on these cell types include reactivated developmental pathways, innate and acquired immune responses, and changes in cell function that result from physical stresses, perturbed blood flow, and biochemical stimuli. Our general approach is to characterize these responses at the molecular level, in cultured cells, and in mouse models that reflect specific types of vascular injury, including atherosclerosis, mechanical trauma, and transplant-associated arteriosclerosis.</p>
<p>Fat proteins are important regulators of cell growth and planar cell polarity. We have linked the atypical cadherin adhesion molecule Fat1 to significant effects on mammalian vascular remodeling. Our studies in VSMCs show that Fat1 interacts with beta-catenin to limit canonical Wnt signaling, a core developmental pathway that regulates many aspects of metazoan embryogenesis, and with Atrophin proteins to control VSMC directional migration. Recent findings suggest that Fat1 is an important regulator of VSMC growth and differentiation in injured vessels, and ongoing studies aim to understand the intracellular and extracellular signals that emanate from Fat1 in cis- and trans-signaling modes. Direct studies of beta-catenin indicate that its expression in VSMCs is required for vascular formation in development and important in adult arterial injury response. Efforts to understand beta-catenin’s essential function in these settings are underway.</p>
<p>Diabetes and obesity are important risk factors for cardiovascular disease. We are investigating how allograft inflammatory factor-1 (Aif-1), a 17 kD Ca2+-binding protein contributes to these conditions. Specific Aif-1 isoform-dependent functions that underlie effects on macrophage migration, phagocytosis, survival, and inflammatory signaling are subjects of ongoing studies. Finally, in collaboration with Richard Stanley, we have characterized a role for colony stimulating factor-1 (CSF-1), the main regulator of macrophage survival, proliferation, and differentiation, in control of transplant-associated arteriosclerosis, the major barrier to long-term success of organ transplants. Surprisingly, this effect appears to involve VSMC-associated CSF-1 in an autocrine/juxtacrine mechanism that is largely independent of macrophages.</p>
<p>Ongoing work in these areas involves defining the molecular bases for these observations. By identifying such novel mechanisms, we hope to find new targets for therapeutic intervention to improve vascular disease prevention and treatment.</p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span>Riascos-Bernal D, Chinnasamy P, Cao L, Dunaway CM, Valenta T, Basler K, Sibinga, NES. β-Catenin C-terminal signals suppress p53 and are essential for artery formation. <em>Nature Communications, </em>2016 Aug 8;7:12389. PMID: 27499244</p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">2.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span>Cao L, Riascos-Bernal D, Chinnasamy P, Dunaway C, Pujato M, Fiser A, Sibinga NES. Control of mitochondrial function and cell growth by the atypical cadherin Fat1.<em> Nature</em>, 2016 Nov 9;539(7630):575-578. PMID: 27828948.</p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">3.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span>Riascos-Bernal DF, Chinnasamy P, Gross JN, Almonte V, Egaña-Gorroño L, Parikh D, Jayakumar S, Guo L, Sibinga NES. Inhibition of smooth muscle β-catenin hinders neointima formation after vascular injury. <em>Arterioscler Thromb Vasc Biol, </em><span style="font-family: Times;">2017 May;37(5):879-888. PMID: 28302627.</span></p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">4.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><span style="font-family: Times;">Egaña-Gorroño L, Chinnasamy P, Casimiro I, Almonte VM, Parikh D, Oliveira-Paula<sup> </sup>GH, Jayakumar S, Law C, Riascos-Bernal DF, Sibinga NES. Allograft Inflammatory Factor-1 Supports Macrophage Survival and Efferocytosis and Limits Necrosis in Atherosclerotic Plaques. <em>Atherosclerosis</em>, 2019 Oct;289:184-194. PMID: 31439353.</span></p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">5.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><span style="font-family: Times;">Becher T, Riascos-Bernal DF, Kramer DJ, Almonte VM, Chi J, Tong T, Oliveira-Paula GH, Koleilat I, Chen W, Cohen P, Sibinga NES. Three-Dimensional Imaging Provides Detailed Atherosclerotic Plaque Morphology and Reveals Angiogenesis after Carotid Artery Ligation. Circ Res. 2020 Feb 28;126(5):619-632. PMID: 31914850. PMCID: PMC7047629.</span></p>
<p class="MsoNormal" style="margin: 0in 4.3pt 6pt 0.75in; font-size: 12pt; font-family: Calibri, sans-serif; text-indent: -0.25in;"><span style="font-family: 'Times New Roman', serif;">6.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><span style="font-family: 'Times New Roman', serif;">Parikh D, Riascos-Bernal DF, Egaña-Gorroño L, Jayakumar S, Almonte V, Chinnasamy P, Sibinga NES. Allograft inflammatory factor-1-like is not essential for age dependent weight gain or HFD-induced obesity and glucose insensitivity. <em>Sci Rep.</em> 2020 Feb 27;10(1):3594. PMID: 32107417. PMCID: PMC7046694.</span></p>
<p class="MsoNormal" style="margin: 0in 4.3pt 6pt 0.75in; font-size: 12pt; font-family: Calibri, sans-serif; text-indent: -0.25in;"><span style="font-family: 'Times New Roman', serif;">7.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><span style="font-family: 'Times New Roman', serif;">Chen W, Fitzpatrick J, Sozio SM, Jaar BG, Estrella MM, Riascos-Bernal DF, Wu TT, Qiu Y, Kurland IJ, Dubin RF, Chen Y, Parekh RS, Bushinsky DA, Sibinga NES. Identification of Novel Biomarkers and Pathways for Coronary Artery Calcification in Nondiabetic Patients on Hemodialysis Using Metabolomic Profiling. Kidney360. 2021 February;2(2):279-289. PubMed PMID: 34723191; PubMed Central PMCID: PMC8553022; DOI: 10.34067/kid.0004422020.</span></p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">8.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span>Almonte VM, Uriyanghai U, Egaña-Gorroño L, Parikh D, Oliveira-Paula GH, Zhang J, Jayakumar S, Riascos-Bernal DF, Sibinga NES. PLX3397, a CSF1 receptor inhibitor, limits allotransplantation-induced vascular remodeling. <em>Cardiovasc Res.</em> 2021 Sep 3:cvab289. doi: 10.1093/cvr/cvab289. Online ahead of print. PMID: 34478521.</p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">9.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span>Lituma PJ, Woo E, O’Hara BF, Castillo PE, Sibinga NES, Nandi S. Altered synaptic connectivity and brain function in mice lacking microglial adapter protein Iba1. <em>Proc Nat Acad Sci U S A. 2021</em>, Nov 16;118(46):e2115539118. doi: 10.1073/pnas.2115539118. PMID: 34764226. PMCID: PMC8609554.</p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">10.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span>Riascos-Bernal DF, Maira A, Sibinga NES. The Atypical Cadherin FAT1 Limits Mitochondrial Respiration and Proliferation of Vascular Smooth Muscle Cells. <em>Front Cardiovasc Med.</em> 2022 May 11;9:905717. doi: 10.3389/fcvm.2022.905717. PMID: 35647082</p>
<p class="MsoListParagraph" style="margin: 0in 13.7pt 6pt 0.75in; font-size: 12pt; font-family: 'Times New Roman', serif; text-indent: -0.25in;"><span style="font-family: Times;">11.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';"> </span></span><span style="font-family: Times;">Parikh D, Jayakumar S, Oliveira-Paula GH, Almonte V, Riascos-Bernal DF, Sibinga NES. Allograft inflammatory factor-1-like is a situational regulator of leptin levels, hyperphagia, and obesity. <em>iScience</em>. 2022 Sep 3;25(10):105058. doi: 10.1016/j.isci.2022.105058. eCollection 2022 Oct 21. PMID: 36134334 </span></p>
Mark Shlomovich
Albumin Dialysis
Care of children before and after solid organ transplantation
<p>Mark Shlomovich, MD, is Director, Extracorporeal Liver Support and Director, Pediatric Critical Care Transport at Children’s Hospital at Montefiore and Assistant Professor, Pediatrics at Montefiore-Einstein. Dr. Shlomovich’s clinical focus is on the care of critically ill children with abdominal organ failure, transplantation and post-surgical care. He also focuses on the safe transportation of critically ill children.</p><p>In 2006, Dr. Shlomovich earned his Bachelor of Science in biology from Towson University. He then attended University of Connecticut School of Medicine earning his Doctor of Medicine in 2010. His postgraduate training began at SUNY Downstate Medical Center with a four-year pediatric residency, where he was Chief Pediatric Resident in his final year. He then came to Children's Hospital at Montefiore for a pediatric critical care fellowship, which he completed in 2017.</p><p>Dr. Shlomovich’s research interests are in the use of artificial liver support technology, as well as the care of children in liver failure before and after transplantation. In addition, he investigates the safety and efficiency of the transportation of critically ill children. He has shared his research through peer-reviewed journals and abstracts, and is an ad hoc reviewer for BMC Nephrology.</p><p>Dr. Shlomovich is board certified in general pediatrics and pediatric critical care medicine. He is a member of the Society of Critical Care Medicine and the American Academy of Pediatrics.</p>
Matthew D. Shaines
<p>Dr. Matthew Shaines completed a medical degree at SUNY Downstate Medical Center - Brooklyn and an internal medicine residency at Montefiore/Einstein. He was then recruited to the Einstein faculty at Montefiore and became one of the initial group of hospitalists who founded the Teaching Hospitalist Program at Montefiore in 2004.</p>
<p>Dr. Shaines has served as Assistant Director of the Hospitalist Service, managing the Moses Teaching Hospitalist Program; founding Director of the Medicine Consult Service, creating a dedicated medicine consult rotation for the housestaff, with a mission of high quality service and education on topics pertaining to consultative and perioperative medicine; Associate Program Director for the Internal Medicine Residency Program, serving as a liaison between the program and the Division of Hospital Medicine. In 2018 he was appointed as the Associate Chief of Hospital Medicine for Education.</p>
<p>His teaching and academic interests are in clinical reasoning, quality improvement and faculty development. He serves as the lead vignette reviewer for Montefiore’s annual Division of General Internal Medicine/Division of Hospital Medicine SGIM/SHM scholarly review process, which helps to review and critique abstracts, posters and oral presentations prior to submission.</p>
Scott H. Shaffer
<p><span>Scott Shaffer, MD is assistant professor of psychiatry and behavioral sciences and pediatrics at the Albert Einstein College of Medicine. He is director of the Child and Adolescent Psychiatry Consult/Liaison Service at the Children's Hospital at Montefiore, and is the deputy training director of the child and adolescent psychiatry fellowship at the Albert Einstein College of Medicine. He completed his residency in psychiatry at the Alpert Medical School of Brown University, and his fellowship in child and adolescent psychiatry at the New York University School of Medicine. </span></p>
<p>Dr. Shaffer is a board member of the New York Council on Child and Adolescent Psychiatry. He is also chair of the Advisory Council for the Gold Humanism Honor Society and is a member of the Arnold P Gold Foundation Board of Trustees. </p>
Dr. Shaffer’s clinical focus is around the evaluation and treatment of somatic symptom disorders, autism spectrum disorder, and medical education. His research focus is on somatic symptom disorders and medical education.
<p>Samuels A, Tuvia T, Patterson D, Briklin O, <strong>Shaffer S</strong>, Walker A. <a href="https://www.ncbi.nlm.nih.gov/pubmed/31267759/">Characteristics of Conversion Disorder in an Urban Academic Children's Medical Center. </a>Clin Pediatr (Phila). 2019 Jul 3; [Epub ahead of print] PubMed PMID: 31267759.</p>
<p> </p>
<p>Denysenko L, Sica N, Penders T, Philbrick K, Walker A, <strong>Shaffer S, </strong>Zimbrean P, Freudenreich O, Rex N, Carroll B, Francis A. Catatonia in the medically ill: Etiology, Diagnosis, and treatment. The Academy of Consultation-Liaison Psychiatry Evidence-based Medicine Subcommittee Monograph. Annals of Clinical Psychiatry 2018:30(2), 140-155.</p>
<p> </p>
<p><strong>Shaffer S</strong>., Fuentes J. On or off the “Spectrum”? The complexity of screening and diagnosing autism spectrum disorder (ASD). JAACAP Connect. Volume 1 Issue 2, Fall 2014.</p>
<p><strong> </strong></p>
<p>Philip NS, <strong>Shaffer S</strong>, Banik D, Johnson B: Supportive Psychotherapy- a Crash Course for Medical Students. Academic Psychiatry 2010: 34:1, 57-60.</p>
<p>Scott Shaffer, MD, is Director of Child and Adolescent Psychiatry Consult-Liaison Service and Deputy Director of Training, Child and Adolescent Psychiatry. He is also an Assistant Professor at our Albert Einstein College of Medicine.
</p><p>After receiving his Bachelor of Arts degree in Biological Sciences from Rutgers University in 2003, Dr. Shaffer continued his education at Rutgers-Robert Wood Johnson Medical School where he earned his Doctor of Medicine degree in 2006. He earned his first residency in General Psychiatry from Warren Alpert Medical School of Brown University in 2010 and his second residency in Child and Adolescent Psychiatry from the New York University School of Medicine in 2012.
</p><p>Dr. Shaffer’s clinical focus is around the evaluation and treatment of somatic symptom disorders, autism spectrum disorder, and medical education. His research focus is on somatic symptom disorders and medical education.
</p><p>Dr. Shaffer is board certified and involved in a number of committees. He is Chair of the Nominating Committee and on the Advisory Council for the Gold Humanism Honor Society, a program of the Arnold P. Gold Foundation. Along with being a Board Member for the New York Council of the American Academy of Child and Adolescent Psychiatry he is also Co-Chair of their Medical Student Subcommittee. At the Albert Einstein College of Medicine, Dr. Shaffer serves as a co-chair for the Committee on Admissions, and is a member of the Clinical Skills Assessment Subcommittee, and the Child Psychiatry Executive Training Committee.
</p><p>He is an active member of the American Academy of Child and Adolescent Psychiatry, New York Council of the American Academy of Child and Adolescent Psychiatry, and Gold Humanism Honor Society.
</p>
Adarsha Selvachandran
Scott J. Schafler
Shawn K. Samuel
Jillian L. Rosengard
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Arial, sans-serif; line-height: 16.8667px;">Jillian L. Rosengard, MD, is an attending physician and Associate Professor of Neurology at Montefiore Einstein. She specializes in the diagnosis and management of seizures and epilepsy. She has a particular interest in treating patients with intractable epilepsy and caring for women with epilepsy during their pregnancies, as well as medical education.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Arial, sans-serif; line-height: 16.8667px;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Arial, sans-serif; line-height: 16.8667px;">After obtaining her Bachelor of Arts at Harvard in 2008, Dr. Rosengard earned her Doctor of Medicine at Mount Sinai School of Medicine in 2012. She completed an internship in internal medicine at New York University Langone Medical Center in 2013 before completing her residency in neurology at Mount Sinai Medical Center in 2016, where she served as Chief Resident. Dr. Rosengard then completed a fellowship in clinical neurophysiology at Einstein in 2017.</p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Arial, sans-serif; line-height: 16.8667px;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Arial, sans-serif; line-height: 16.8667px;">Dr. Rosengard's research focuses on the impact of Covid-19 on patients with epilepsy as well as seizure prediction. She also participates in drug trials for new anti-seizure medications through Montefiore’s Clinical Research Center. She has been Principal Investigator and Co-Principal Investigator on several research projects, and her work has been published in numerous peer-reviewed journals and textbooks. Dr. Rosengard has given national presentations and has been a reviewer for scientific journals including <em>Neurology, Epilepsy & Behavior </em>and the<em> Journal of the Neurological Sciences.</em></p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Arial, sans-serif; line-height: 16.8667px;"><em> </em></p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Arial, sans-serif; line-height: 16.8667px;">Dr. Rosengard is board certified in Neurology and Epilepsy by the American Board of Psychiatry and Neurology. She is a member of the American Academy of Neurology and the American Epilepsy Society. In 2023, Dr. Rosengard was elected into the Leo M. Davidoff Society for outstanding achievement in the teaching of medical students, and she has been named a New York Super Doctors Rising Star for several years.</p>
Dr. Rosengard specializes in the diagnosis and management of seizures and epilepsy. She has a particular interest in treating women with epilepsy during their pregnancies as well as medical education.<br />
Dr. Rosengard's research focuses on the Covid-19 pandemic's inpatient on patients with epilepsy as well as seizure prediction. She also participates in drug trials for new anti-seizure medications through Montefiore Clinical Research Center.<br /><quillbot-extension-portal></quillbot-extension-portal>